Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

BioPharma« Terug naar discussie overzicht

Geron Corporation

157 Posts
Pagina: «« 1 2 3 4 5 6 ... 8 »» | Laatste | Omlaag ↓
  1. [verwijderd] 29 maart 2018 23:16
    quote:

    Nachtraver schreef op 29 maart 2018 23:06:

    Ik had geen mogelijkheid om de beurs te volgen en heb ze in de verkoop gezet voor 4,75.
    En tot mijn verbazing (en tevredenheid) was ik ze ergens rond half vier kwijt.

    Gisteren overigens wel in de rats gezeten.
    Denk niet dat ik morgen nog ga instappen.
    Ik wel vandaag op 4.25. Het zakte niet door dus wel vertrouwen door de grote omzetten.
  2. indianrider 12 april 2018 23:12
    Why Geron Corporation Stock Is on the Rise Today

    April 12, 2018
    What happened

    Shares of Geron Corporation (NASDAQ: GERN), a small-cap oncology company partnered with Johnson & Johnson (NYSE: JNJ) for the telomerase inhibitor imetelstat, are heading up this morning on sky-high volume. What's driving this sudden surge?

    Presumably, Geron's shares are moving northward in anticipation of J&J's first-quarter earnings release scheduled for next Tuesday. Investors appear to be bidding Geron's stock up on the working assumption that J&J will provide a broad clinical pipeline update next week, and that this update will feature imetelstat as a top product candidate. J&J, after all, has consistently listed imetelstat as one of its top blockbuster candidates over the course of the last two years.

    Geron's shares are up by 12.7%, as of 11:06 a.m. EDT.

    A green tree in the shape of the letter X with falling leaves on the end caps
    A green tree in the shape of the letter X with falling leaves on the end caps
    Image source: Getty Images.

    So what

    Of course, the big-ticket item here is the fact that imetelstat's third internal review for its advanced myelofibrosis trial called IMbark has now been completed. J&J probably has a pretty good idea at this stage of whether it intends to hold on to imetelstat's rights. So it's easy to understand why investors are excited about next week's events.

    Now what

    Last May, J&J discussed its clinical pipeline at length with investors, where imetelstat was listed as a "late-stage blockbuster product" candidate. At the time, the reaction among Geron investors was somewhat subdued because everyone was painfully aware that the drug still had a long way to go in terms of development to achieve this lofty goal.

    Fast-forward a year, imetelstat is now on the cusp of two major clinical updates for advanced myelofibrosis and myelodyspastic syndromes. So if imetelstat remains on J&J's list of top experimental medicines next week, this stock should easily push past its 52-week highs. That rosy scenario is far from guaranteed, but next week could turn out to be a watershed moment in the biotech's life cycle. Stay tuned.

    More From The Motley Fool

    George Budwell owns shares of Geron. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has the following options: short May 2018 $140 calls on Johnson & Johnson. The Motley Fool has a
  3. [verwijderd] 22 mei 2018 19:00
    quote:

    De opa van Juul schreef op 16 mei 2018 14:28:

    Volgens mij gaat er op korte termijn iets gebeuren. Iemand iets over de jaarlijkse aandeelhoudersvergadering vernomen van gisteravond?
    Koers gaat nu toch weer serieus omhoog en staat inmiddels weer ruim boven de 4 dollar. Wie weet zet het door succes
  4. indianrider 23 mei 2018 08:46
    quote:

    MVo_ schreef op 22 mei 2018 22:21:

    Blij dat ik vorige week bescheiden ben ingestapt. Overal op de message boards zie je dat dit aandeel kapot geshort is de afgelopen tijd. Nu lijkt hier wellicht een einde aan te komen en kunnen we naar een serieuze koers toe.
    Met welke reden zouden ze stoppen ?
157 Posts
Pagina: «« 1 2 3 4 5 6 ... 8 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.